domingo, 10 de julio de 2016

Tier 1 Genomic Applications Toolkit for Public Health Departments|Lynch 4|Genomics|CDC

Tier 1 Genomic Applications Toolkit for Public Health Departments|Lynch 4|Genomics|CDC

Genomics & Health Impact Update banner with DNA in background



Tier 1 Toolkit with DNA

Tools for Bidirectional Cancer Registry Reporting to Identify Individuals at Risk for Lynch Syndrome

The following materials were developed to support state programs using bidirectional cancer registry reporting to identify individuals at risk for Lynch syndrome. State health departments are encouraged to customize the materials to meet their needs. Materials are categorized by those intended for patients and for healthcare providers, but materials may be suitable for multiple audiences. Please note that some materials will need to be filled out with state-specific information, as noted below.
Information for Patients
Information for Providers
Reporting Tools

CDC tools and information on LS Tier 1

The LS State Burden of Disease Estimator Tool

Estimated number of persons with Lynch syndrome (LS) who could be identified by screening all persons with newly diagnosed invasive colorectal cancer (CRC)

StateIncident cases invasive CRCaEstimated numbers with LSb
2%3%4%
Alabama2,333477093
Alaska277<10<1011
Arizona2,332477093
Arkansascd1,400284256
California14,445289433578
Colorado1,683345067
Connecticut1,724345269
Delaware434<101317
District of Columbia264<10<1011
Florida8,995180270360
Georgia3,74875112150
Hawaii733152229
Idaho551111722
Illinois6,255125188250
Indiana2,9585989118
Iowa1,689345168
Kansas1,318264053
Kentucky2,419487397
Louisiana2,408487296
Maine666132027
Maryland2,282466891
Massachusetts2,7855684111
Michigan4,49490135180
Minnesotac    
Mississippi1,619324965
Missouri2,8975887116
Montana519101621
Nebraska905182736
Nevada1,059213242
New Hampshire511101520
New Jersey4,17784125167
New Mexico802162432
New York9,311186279372
North Carolina3,94979118158
North Dakota353<101114
Ohio5,235105157209
Oklahoma1,702345168
Oregon1,612324864
Pennsylvania6,866137206275
Rhode Island498101520
South Carolina2,024406181
South Dakota458<101418
Tennessee2,9806089119
Texas8,959179269358
Utah691142128
Vermont278<10<1011
Virginia3,0656192123
Washington2,6515380106
West Virginia1,036213141
Wisconsin2,387487295
Wyoming260<10<1010
b- Moreira L, et al. JAMA. 2012 Oct 17;308(15):1555-65.
Identification of Lynch syndrome among patients with colorectal cancer.
c-Minnesota and Arkansas cancer incidence data for 2010 are not available; 2009 data presented
d-Arkansas cancer incidence data are from 2009

Explanation of estimates

We estimated, by state, the number of persons with Lynch syndrome (LS) who could be identified by screening all persons with newly diagnosed invasive colorectal cancer (CRC). These estimates are based on the numbers of incident CRC cases reported by state cancer registries in 2010 (ref 1). To approximate the proportion of persons with CRC who could be expected to have LS, we used the estimate of 3% obtained by Moreira, et al, in a combined analysis of population-based studies in the U.S., Canada, Australia, and Europe (ref 2). To emphasize that this proportion is an imprecise approximation, we display estimates based on proportions of 2% and 4% for comparison.
Several factors that could influence these estimates have not been taken into account. These factors could include changes in state populations or CRC incidence since 2010; differences in LS prevalence among different racial and ethnic groups, which vary in their distribution among the states; and errors or uncertainty in the data used to calculate the estimates.
  1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2010 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. Available at:https://nccd.cdc.gov/uscs/.
  2. Moreira L, Balaguer F, Lindor N, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012;308:1555-65.

No hay comentarios:

Publicar un comentario